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INTRODUCTION
Acute pancreatitis is one of  the major and serious 
complications after diagnostic or therapeutic endoscopic 
retrograde cholangiopancreatography (ERCP). Despite 
the technical improvements of  recent years and the 
experience of  endoscopists, the incidence has not 
decreased and it ranges from 1% to 10% of  patients[1]. 
The most severe forms of  pancreatitis, with pancreatic 
necrosis, multi-organ failure and even death, occurs in 
0.3%-0.6% of  patients, but a silent increase in serum 
pancreatic enzymes could be observed in up to 70% of  
patients[2]. The triggering mechanism of  the inflammatory 
response remains unclear and different pharmacological 
agents has been tested to prevent post-ERCP pancreatitis 
including anti-inflammatory steroids, somatostatin analogs, 
heparin, protease inhibitors and anti-inflammatory 
cytokines[3-6]. Only few drugs showed some efficacy to 
prevent post-ERCP pancreatitis like recently nitrate 
therapy by decreasing the pancreatic ductal pressure 
or diclofenac by lowering inflammatory process[7,8]. 
Therefore, the availability of  effective drugs and strategy 
of  chemoprevention remain as unsettled points in the 
pharmacological prophylaxis of  post-ERCP pancreatitis[5-8], 
leading to the apparition of  endoscopic procedure such as 
pancreatic sphincterotomy to try to decrease the risk of  
post-ERCP pancreatitis[9].
Recent evidences indicate an important role for the 
peroxisome proliferator-activated receptors (PPARs) in the 
regulation of  both inflammation and lipid metabolism[10]. 
In particular, it has been reported, using an experimental 
model of  cerulein-induced pancreatitis, that the pancreatic 
inflammation and tissue injury was markedly reduced 
by the administration of  PPARγ agonists[11]. PPARγ is a 
member of  the nuclear hormone receptor superfamily 
originally reported to be expressed at high levels in 
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Abstract
AIM: To determine the effects of prophylactic peroxi-
some proliferator-activated receptor (PPARγ) agonist 
administration in an experimental model of post-
endoscopic retrograde cholangiopancreatography (post-
ERCP) acute pancreatitis.
METHODS: Post-ERCP pancreatitis was induced in 
male Wistar rats by infusion of contrast medium into 
the pancreatic duct. In additional group, rosiglitazone, a 
PPARγ agonist, was administered 1 h before infusion of 
contrast medium. Plasma and pancreas samples were 
obtained 6 h after the infusion.
RESULTS: Infusion of contrast medium into the pan-
creatic duct resulted in an inflammatory process 
characterized by increased lipase levels in plasma, and 
edema and myeloperoxidase activity (MPO) in pancreas. 
This result correlated with the activation of nuclear 
factor κB (NFκB) and the inducible NO synthase (iNOS) 
expression in pancreatic cells. Rosiglitazone reduced 
the increase in lipase and the level of edema and the 
increase in myeloperoxidase as well as the activation of 
NFκB and iNOS expression.
CONCLUSION: A single oral dose of rosiglitazone, given 
1 h before post-ERCP pancreatitis induction is effective 
in reducing the severity of the subsequent inflammatory 
process. The protective effect of rosiglitazone was 
associated with NFκB inhibition and the blockage of 
leukocyte infiltration in pancreas.
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adipose tissue and to play a critical role in adipocyte 
differentiation, glucose metabolism and lipid storage. In 
an experimental model of  intestinal ischemia-reperfusion, 
a more severe injury was observed in PPARγ-deficient 
mice and protection against local and remote tissue injury 
in mice treated with a PPARγ-activating ligand[12]. Then, it 
has been demonstrated that PPARγ ligands can inhibit the 
inflammatory response by decreasing IL-6, IL-1β, TNFα 
and the inducible NO synthase (iNOS) by interfering with 
nuclear factor κB (NFκB) and AP1[13,14]. The aim of  this 
study was to investigate the efficacy of  prophylactic PPARγ 
agonist treatment in reducing the pancreatic damage in an 
experimental post-ERCP acute pancreatitis model.
MATERIALS AND METHODS
Reagents
Reagents for SDS-PAGE and nitrocellulose membranes 
were from Amersham Pharmacia (Buckinghamshire, 
England). Antibodies against p65, PPARγ and Histone 
H1 were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA), antibody against iNOS was obtained from BD 
Transduction (Heildelberg, Germany), antibody against 
β-actin and the secondary antibody linked to horseradish 
peroxidase were from Sigma Chemicals (St Louis, MO). 
The following reagents were obtained from Sigma 
Chemicals (St Louis, MO): NaVO3, NaF, Nonidet P40, 
ethidium bromide, Hexadecyltrimethylammonium bromide, 
Tetramethylbenzidine, DMSO, H2O2.
Post-ERCP pancreatitis model
Male Wistar rats (250-300 g) were used for all experiments. 
Animals were housed in light-dark cycle regulated, air 
conditioned (23℃) and air humity (60%) animal quarters, 
given free access to drinking water and standard food pellets 
until 12 h prior to the experiment, at which point food 
was withdrawn. Animal care was in compliance with the 
European Community (Directive 86/609/EEC) for the use 
of  experimental animals and the institutional committee 
of  animal care and research approved it. Rats were 
anaesthetized with ip injection of  sodium pentobarbital (10 
µL/kg). The biliopancreatic duct was cannulated through 
the duodenum and the hepatic duct was closed by a small 
bulldog clamp. Post-ERCP pancreatitis was induced by 
retrograde infusion into the biliopancreatic duct of  low 
osmolarity contrast medium Meglumine/Sodium Ioxaglate 
(Hexabrix 320) in a volume of  10 µL/kg using a Harvard 
'22' infusion pump (Harvard Instruments, Edenbridge, 
UK). Control animals were subjected to anesthesia and 
laparotomy[15]. 
Experimental design
In the first set of  experiments, we evaluated the severity 
of  pancreatic damage and tissue inflammation after the 
infusion of  contrast medium into the pancreatic duct. For 
this purpose, rats (n = 6 for each group) were sacrificed at 
0, 3, 6 and 24 h after infusion and samples of  pancreatic 
tissue and plasma were obtained, immediately frozen and 
maintained at -80℃ until assayed.
In a second series of  experiments, a PPARγ agonist 
(Rosiglitazone, AVANDIA® GlaxoSmithKline, Brentford, 
UK) was administered (10 mg/kg intragastric bolus) 1 
h before infusion of  contrast medium (n = 8 for each 
group)[11]. Samples of  plasma and pancreas were obtained 
6 h after infusion.
Edema
The extent of  pancreas edema was assayed by measuring 
tissue water content. Freshly obtained samples of  pancreas 
were weighted on aluminum foil, dried for 24 h at 95℃
and reweighed. The difference between wet and dry tissue 
weight was calculated and expressed as a tissue wet: dry 
mass ratio.
Myeloperoxidase activity
Neutrophil infiltration was assessed by measuring 
myeloperoxidase (MPO) activity. Myeloperoxidase 
w a s m e a s u r e d p h o t o m e t r i c a l l y w i t h 3 , 3 ’ , 5 , 5 ’
-tetramethylbenzidine as a substrate[16]. Samples were 
macerated with 5 g/L hexadecyltrimethylammoniu
m bromide in 50 mmol/L phosphate buffer pH 6.0. 
Homogenates where then disrupted for 30 s using a 
Labsonic (B.Braun) sonicator at 20% power and submitted 
to three cycle of  snap freezing in dry ice and thawing 
before a final 30 s sonication. Samples were incubated at 
60℃ for 2 h and then spun down at 4000 g for 12 min. 
Supernatants were collected for myeloperoxidase assay. 
Enzyme activity was assessed photometrically at 630 nm. 
The assay mixture consisted of  20 µL supernatant, 10 µL 
tetramethylbenzidine (final concentration 1.6 mmol/L) 
dissolved in DMSO and 70 µL H2O2 (final concentration 
3.0 mmol/L) diluted in 80 mmol/L phosphate buffer pH 
5.4. An enzyme unit is defined as the amount of  enzyme 
that produces an increase of  1 absorbance unit per minute.
NFκB and PPARγ  DNA binding
Binding of  NFκB p65 subunit to the NFκB binding 
consensus sequence 5’-GGGACTTTCC-3’ and binding 
of  PPARγ to the PPRE binding consensus sequence 5’
-AACTAGGTCAAAGGTCA-3’ were measured with the 
ELISA-based TransAM kits (Active Motif, Carlsbad, CA) 
using tissue nuclear extracts. This assay is performed in 
96-well plates coated with an oligonucleotide containing the 
binding consensus sequence. The active forms in nuclear 
extracts can be detected using specific Abs for epitopes 
that are accessible only when the subunits are activated and 
bound to its target DNA. Specificities were checked by 
measuring the ability of  soluble wild-type oligonucleotides 
to inhibit binding.
Western blot
Pancreatic tissue was lysed by using the Nuclear Extract 
Kit from Active Motif  (Carlsbad, CA) following the 
manufacturer conditions for preparation of  cytoplasmatic 
and nuclear extracts. SDS-PAGE was performed using 
100 g/L or 120 g/L acrylamide gels. Proteins were 
electrotransfered to nitrocellulose membrane and probed 
with primary Ab (anti-p65, 1/1000; anti-PPARγ, 1/200; 
anti-iNOS, 1/400; anti-β-actin, 1/400; anti-Histone 
H1, 1/500). The membranes were incubated with 
corresponding horseradish peroxidase-linked secondary 
Ab, washed and subsequently incubated with ECL reagents 
from Amersham Pharmacia (Buckinghamshire, England) 
before exposure to high performance chemiluminescence 
films. Gels were calibrated using Bio-Rad standard proteins 
(Hercules, CA) with markers covering a 7-240 kDa range.
Protein measurement
Total protein concentration in homogenates was deter-
mined using a commercial kit from BioRad (Munich, 
Germany).
Lipase
Plasma lipase was determined by using commercial kits 
from Randox (Antrim, UK), according to the supplier’s 
specifications.
Histological study
Pancreatic tissue samples were taken and fixed in 40 
g/L neutral buffered formaldehyde solution, paraplast-
embedded, cut into 5 µm sections and stained with 
hematoxilyn-eosin for light microscopy. Two different 
observers evaluated randomly ten fields from each 
animal and cell infiltration was recorded blindly on 
photomicrographs.
Statistical analysis
Data have been expressed as mean ± SE. Means of  
different g roups were compared using a one-way 
analysis of  variance. Tukey’s multiple comparison test 
was performed for evaluation of  significant differences 
between groups. Differences were assumed to be 
significant when P < 0.05.
RESULTS
ERCP-induced pancreatic damage 
The evolution of  pancreatic damage was evaluated by 
measuring plasma lipase and tissue MPO activity at 
different time points after pancreas infusion of  contrast 
medium (Figure 1). A rapid and significant increase was 
observed in plasma lipase activity that achieved a peak 
between 3 and 6 h after surgery. By contrast, MPO activity 
was not increased until 6 h after infusion and remained 
increased until the end of  experiment (24 h). Since in this 
model the inflammation required 6 h to be established, we 
selected this time point for the rest of  experiments.
Treatment with rosiglitazone induced pancreatic activation 
of PPARγ
To evaluate the efficacy of  rosiglitazone to induce PPARγ 
activation in the pancreatic tissue, we measured, on 
nuclear extracts, the levels of  DNA binding activity to 
an immobilized oligonucleotide containing the PPRE 
sequence. Binding activity was significantly increased in 
rosiglitazone-treated animals (Figure 2A). By contrast, 
in non-treated animals, ERCP-induced pancreatitis was 
not associated with changes in pancreatic PPARγ activity. 
These results were confirmed by western blot analysis of  
the translocation of  PPARγ into the nuclear fraction upon 
rosiglitazone treatment (Figure 2B).
Rosiglitazone reduced the ERCP-induced pancreatic 
damage 
Both tissue edema and plasma lipase activity showed 
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Figure 1  Plasma lipase and pancreas MPO activity after retrograde infusion of 
contrast media. (aP < 0.05 vs t = 0).
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Figure 2  PPARγ activation. A: PPARγ DNA binding activity of pancreas nuclear 
extracts expressed as % of control activity. No significant differences were 
observed on PPARγ binding to DNA after pancreatitis induction. By contrast, 
PPARγ binding to DNA is strongly induced by rosiglitazone in both control and 
pancreatitis groups. aP < 0.05 Rosiglitazone-treated vs vehicle-treated groups. 
B: Western blot of nuclear PPARγ confirmed the nuclear translocation of PPARγ 
protein after rosiglitazone administration in both control and pancreatitis groups. 
Western blot was representative of three different experiments.
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increased levels 6 h after contrast media infusion (Figure 3). 
Pre-treatment with rosiglitazone significantly reduced these 
increases, but not to control levels. Histological findings 
also showed a clear reduction on pancreatic interlobular 
edema (Figure 4). No acinar necrosis was observed after 
contrast-media infusion.
ERCP-induced inflammatory response was inhibited by 
rosiglitazone
When measuring the MPO activity, we observed that 
the increase induced by contrast medium infusion was 
completely abrogated by pre-treatment with rosiglitazone 
(Figure 5). This result was confirmed by histological 
results. In ERCP group, areas of  intense cell infiltration 
with extravasation of  leukocytes to the interacinar space 
were observed (Figure 4C). Treatment with rosiglitazone 
completely prevented the infiltration of  leukocytes (Figure 
4D). 
Rosiglitazone prevented the ERCP-induced NFkB-
activation
In order to evaluate the possible involvement of  NFκB on 
this anti-inflammatory effect, we measured the levels of  
p65 DNA binding activity in pancreatic nuclear extracts. 
Results indicated that infusion of  contrast media into the 
pancreatic duct induced a significant activation of  NFκB 
(Figure 6A). This increase was completely prevented by 
pre-treatment of  rosiglitazone. The effect of  the PPAR-γ 
agonist on NFκB was confirmed by detecting, by western 
blot, the presence of  p65 subunit of  NFκB into the 
nuclear fraction (Figure 6B). In the ERCP group, p65 
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Figure 3  Pancreatic tissue edema and plasma lipase 
activity 6 h after contrast medium infusion. Retrograde 
administration of contrast medium induced increases 
in edema and lipase activity. These increases were 
partially prevented by pre-treatment of rosiglitazone. 
aP < 0.05 AP vs their corresponding control; cP < 0.05 
rosiglitazone-treated AP group vs vehicle-treated AP 
group.
Figure 4  Histological examination of the pancreas 
(x 200). A: Control pancreas showed normal acinar 
structure; B: No morphological changes were observed 
after rosiglitazone administration in control animals; 
C:  Experimental ERCP-induced pancreatic damage 
reflected in interlobular and interacinar edema and 
areas of leukocyte infiltration (arrows). Acinar necrosis 
was not observed; D: Rosiglitazone pre-treatment 
before contrast medium infusion resulted in a reduced 
edema and absence of leukocyte cell infiltration.
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Figure 5  Myeloperoxidase activity in pancreas. MPO activity was significantly 
increased in post-ERCP induced pancreatitis in comparison with vehicle. 
Rosiglitazone treatment prevented this increase. aP < 0.05 AP vs control; cP < 0.05 
rosiglitazone-treated AP group vs Vehicle-treated AP group.
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translocated into the nucleus and this translocation was 
prevented by pre-treatment of  rosiglitazone.
Rosiglitazone prevented ERCP-induced expression of 
iNOS
Finally, similar result was found when determining the 
expression of  iNOS, an NFκB-dependent enzyme (Figure 
7). In ERCP group, iNOS was strongly induced, and 
pre-treatment with rosiglitazone prevented this increase. 
Interestingly, the enzyme, that is undetectable in control 
animals showed a weak expression in control animals 
treated with rosiglitazone.
DISCUSSION
Since pancreat i t i s represents the most common 
complication after ERCP, different drugs, including 
IL-10, gabexate mesylate, heparin or somatostatin, nitrate 
derivates or diclofenac have been tested to reduce the 
incidence and severity of  post ERCP-pancreatitis. Many of  
these studies, despite the use of  randomized procedures 
were criticized because of  non reproducible results[3]. In 
addition, the multifactorial etiology and pathophysiology 
of  post-ERCP pancreatitis needs to be taken into account. 
Simplified procedures and the absence of  adverse effects 
are required to deliver prophylactic treatment for post-
ERCP pancreatitis. Our study shows that administration 
of  a PPARγ agonist in a single oral dose before starting 
ERCP decreases the severity of  the inf lammatory 
reaction triggered by this procedure. Evidence has been 
accumulated indicating that PPARγ plays a role modulating 
the inflammation. Several studies have demonstrated that 
the use of  PPARγ ligands inhibits the intensity of  the 
inflammatory response in different processes including 
colitis[17], adjuvant-induced arthritis[14], and cerulein-
induced pancreatitis[11]. In vitro, the expression of  
inflammatory mediators such as TNFα, IL-1β, IL-6, iNOS 
or MMP-9[13,18] could be inhibited by PPARγ ligands. These 
findings have raised the possibility that these agents could 
be useful for the treatment of  the inflammatory disorders.
Our results indicate that administration of  rosiglitazone 
before experimental ERCP completely prevented the 
inflammatory response in the pancreas, reflected in a 
reduced MPO activity and the lack of  leukocytes infiltrate 
observed in pancreas. By contrast, increases in lipase 
plasma activity and edema were only partially prevented 
by rosiglitazone. This fact was not unexpected, since 
rosiglitazone prevents the activation of  the inflammatory 
response, but has no effect on the mechanical damage 
related with changes in osmolarity or increased intraductal 
pressure. Pancreatic damage results from both mechanical 
and inflammatory processes associated with intraductal 
activation of  pancreatic proenzymes. Nitrate derivates 
or pancreatic stenting have been proposed to increase 
pancreatic out-f low, diclofenac or IL-10 following 
inflammatory response and somatostatin to decrease the 
intraductal concentration of  pancreatic proenzymes[5-9]. 
Ros ig l i t azone was supposed to ac t on ly on the 
inflammatory-related increases in lipase and edema.
It is known that the activation of  PPARγ results in 
a reduction of  the inflammatory response due to its 
inhibitory effect on main inflammatory signal transduction 
pathways, in particular, NFκB. It has been reported, 
in several experimental models of  pancreatitis, that 
pancreatic damage was associated with increased nuclear 
translocation of  NFκB dimers p65/p50 that trigger the 
transcription and generation of  a broad spectrum of  
inflammatory mediators by pancreatic cells[19]. These 
mediators, including cytokines, chemokines and adhesion 
molecules, generate a microenvironment that promotes 
the recruitment and activation of  inflammatory cells and 
contributes to increasing the extension of  the pancreatic 
damage. Consequently, we have evaluated the involvement 
of  NFκB in the observed anti-inflammatory effect of  
PPARγ in post-ERCP pancreatitis. For this purpose 
we have measured the nuclear translocation and DNA 
binding of  p65, the key component of  NFκB. The results 
indicate that nuclear translocation of  p65 was significantly 
increased after experimental ERCP and this increase was 
completely prevented by pre-treatment of  rosiglitazone. 
This inhibition could explain the lack of  inflammatory 
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Figure 6  NFκB activation. A: NFκB DNA binding activity of pancreas nuclear 
extracts expressed as % of control p65 activity. Post-ERCP induced pancreatitis 
resulted in increased levels of p65 binding activity. This increase was inhibited by 
rosiglitazone pre-treatment. aP < 0.05 AP vs Control; cP < 0.05 rosiglitazone-treated 
AP group vs vehicle-treated AP group; B: Western blot of nuclear p65 confirmed 
the nuclear translocation of p65 protein during ERCP-induced pancreatitis. This 
nuclear translocation was not observed after rosiglitazone administration. Western 
blot was representative of three different experiments.
Figure 7  Inducible NO synthase (iNOS) expression. Western blot of cytoplasmatic 
iNOS showed increased expression of this protein during post-ERCP induced 
pancreatitis. This increase was reduced by rosiglitazone pre-treatment. Results 
are representative of three separate experiments.
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infiltrate observed in pancreas, since NFκB activation is a 
requisite for the generation of  the main pro-inflammatory 
mediators involved in pancreatitis. 
Similar results were observed when measuring the 
expression of  iNOS in pancreatic tissue. This enzyme was 
induced mainly in activated leukocytes in order to generate 
nitric oxide at a cytotoxic concentration as a part of  the 
bactericidal mechanism of  these cells. The presence of  
iNOS in pancreas in post-ERCP pancreatitis confirms 
that an intense inflammatory process was triggered. Since 
the synthesis of  this enzyme is strongly dependent on 
NFκB, it is not a surprise that rosiglitazone treatment 
downregulates the expression of  iNOS. On the other 
hand, the reduced levels of  iNOS could also reflect the 
lack of  cell infiltration that occurs under these conditions.
The blockage of  NFκB activation and the resulting 
inhibition in the NFκB-dependent mediators is of  
importance not only for the local inflammation, but 
also in order to prevent the release into the circulatory 
bloodstream of  pro-inflammatory cytokines that could 
trigger a systemic inflammatory response. Although this 
occurs in a reduced percentage of  patients, the severity 
of  the process justifies the use of  prophylactic measures 
to prevent it despite the failure or the weakness of  many 
previous series.
In conclusion, despite the general limitations of  all 
the animal models relative to clinical setting and the 
multifactorial etiology of  post-ERCP pancreatitis, these 
results suggest that rosiglitazone and other PPARγ 
agonists are potential new therapeutic agents for the 
prevention of  post-ERCP-induced acute pancreatitis. 
It could be administered in an oral dose to the patients, 
shortly before the ERCP. However, further studies are 
needed to determine the proper dose and time-point of  
administration in human patients.
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